Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Key Highlights
- ➤Q3 net income $0.2 million, versus a $7.7 million loss year-over-year
- ➤Q3 net revenue $39.6 million, down 20% year-over-year
- ➤Q3 operating expenses $18.5 million, down 44% year-over-year
- ➤Europe in-market VAZKEPA demand increased an estimated 68% year-over-year
- ➤Cash, cash equivalents and short-term investments reached $323.4 million
Expert Statements
Aaron Berg, President and Chief Executive Officer of Amarin
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value.”
Aaron Berg, President and Chief Executive Officer of Amarin
“International in-market demand grew at a double-digit pace across our partner network reflecting increased adoption by patients and prescribers, and we maintained leadership in the U.S. IPE market amid pricing pressure from generic competition.”
Peter Fishman, Chief Financial Officer of Amarin
“We reported our first profitable quarter in over two years, reflecting our lower expense base and the absence of charges following the completion of our previously announced $70 million cost savings initiatives. We generated positive free cash flow for the fourth consecutive quarter. Our cash balance now exceeds $323 million and our balance sheet remains debt-free.”
Peter Fishman, Chief Financial Officer of Amarin
“We are encouraged by the in-market demand growth for VASCEPA/VAZKEPA across Europe and the rest of the world, reflecting its expanding market presence. We expect this growth to support increased partner supply purchases and related revenue over time as our partner-led sales model matures. The timing and level of product revenue will continue to reflect factors outside our direct control, including partner inventory levels, ordering patterns, as well as market access and pricing. In the U.S., we have efficiently maintained a market leading position in a highly competitive environment which continues to further strengthen our financial foundation.”
Aaron Berg, President and Chief Executive Officer of Amarin
“Our financial results demonstrate the tremendous progress we have made to date, and we believe Amarin is in a stronger position than at any point in our recent history. Building on that and guided by a clear mandate to maximize shareholder value, we continue to work closely with Barclays, our exclusive financial advisor, and remain focused on working through these efforts in a timely and disciplined manner.”
Aaron Berg, President and Chief Executive Officer of Amarin
“Our focus remains on patients and their unmet needs, and we are energized by the potential of new possibilities for VASCEPA suggested by the outcome of this study.”
Aaron Berg, President and Chief Executive Officer of Amarin
“We have long believed that we have a special molecule in IPE, and this study reinforces that conviction by pointing to potential new therapeutic applications for VASCEPA/VAZKEPA. Patent protection in Europe through 2039 provides a durable foundation to evaluate opportunities with high unmet patient needs and their potential to deliver long-term value for patients and shareholders.”
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.
Delivering On Our Performance Objectives “Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA(®)/VAZKEPA(®) (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value,” said Aaron Berg, President & Chief Executive Officer. “International in-market demand grew at a double-digit pace across our partner network reflecting increased adoption by patients and prescribers, and we maintained leadership in the U.S. IPE market amid pricing pressure from generic competition.”
Get started
Create a free account to read the full story.